Declining gut microbial diversity and reduced short-chain fatty acid production in aging creates a destructive feedback loop with mTOR signaling that severely compromises vaccine effectiveness. The research reveals how age-related drops in beneficial SCFAs fail to regulate mTOR activity, leading to suppressed autophagy, chronic inflammation, and impaired T and B cell function that collectively reduce antibody production and immune memory formation. This mechanistic understanding represents a significant advance beyond simply attributing poor vaccine responses to general immunosenescence. The bidirectional nature of this relationship—where SCFA deficiency enables mTOR overactivation, which then further disrupts the microbiota—suggests intervention points that could dramatically improve vaccine outcomes in older adults. The therapeutic implications are substantial, as mTOR inhibitors like rapamycin, targeted probiotics, or dietary interventions to boost SCFA production could potentially restore vaccine efficacy in aging populations. However, most evidence remains preclinical, and the complexity of personalizing interventions based on individual microbiota profiles presents significant implementation challenges. This framework could transform how we approach vaccination strategies for the elderly, moving toward precision medicine approaches that optimize the gut-immune axis.